Sunyoung Kim – Founder and CEO, ViroMed, South Korea

Sunyoung Kim, CEO and founder of ViroMed, reveals his strategy for conquering the US market and the feasibility of his ambitions for ViroMed to become the biotech company with the largest revenues from gene therapy by 2025. He also discusses the areas within the Korean biotech sphere that must develop to truly entrench the country as a dominant player in the global market.  
In short, our technology and disease platforms allow us to develop a number of different products and to target many different diseases
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Already a member? Sign In

Related Interviews

Latest Report